DCPH - The Buzz Show: Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Phase 3 Clinical Study Fails

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Deciphera Pharmaceuticals, Inc. Shares Fell 73% After its INTRIGUE Phase 3 Clinical Study Failed to Meet its Primary Endpoint”

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plummeted over 73% in premarket trading after the company’s INTRIGUE Phase 3 Clinical Study failed to meet its primary endpoint.

While full results from the INTRIGUE Phase 3 clinical study are expected to be presented at an upcoming medical meeting, the study did not achieve the primary efficacy endpoint of improved progression-free survival versus standard of care Sunitinib.

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK ® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia 1 , Canada 2 , China 3 , Hong Kong 4 , Switzerland 5 , Taiwan 6 , and the United States 7

For more information, please visit: Deciphera Pharmaceuticals, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Phase 3 Clinical Study Fails first appeared on Financial Buzz .

For further details see: